843 related articles for article (PubMed ID: 15548764)
21. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG.
Rampe D; Murawsky MK; Grau J; Lewis EW
J Pharmacol Exp Ther; 1998 Aug; 286(2):788-93. PubMed ID: 9694935
[TBL] [Abstract][Full Text] [Related]
22. Time course and voltage dependence of expressed HERG current compared with native "rapid" delayed rectifier K current during the cardiac ventricular action potential.
Hancox JC; Levi AJ; Witchel HJ
Pflugers Arch; 1998 Nov; 436(6):843-53. PubMed ID: 9799397
[TBL] [Abstract][Full Text] [Related]
23. HERG channel (dys)function revealed by dynamic action potential clamp technique.
Berecki G; Zegers JG; Verkerk AO; Bhuiyan ZA; de Jonge B; Veldkamp MW; Wilders R; van Ginneken AC
Biophys J; 2005 Jan; 88(1):566-78. PubMed ID: 15475579
[TBL] [Abstract][Full Text] [Related]
24. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.
Diaz GJ; Daniell K; Leitza ST; Martin RL; Su Z; McDermott JS; Cox BF; Gintant GA
J Pharmacol Toxicol Methods; 2004; 50(3):187-99. PubMed ID: 15519905
[TBL] [Abstract][Full Text] [Related]
25. Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired Long QT syndrome by antiparkinsonian drug budipine.
Scholz EP; Zitron E; Kiesecker C; Lueck S; Kathöfer S; Thomas D; Weretka S; Peth S; Kreye VA; Schoels W; Katus HA; Kiehn J; Karle CA
Naunyn Schmiedebergs Arch Pharmacol; 2003 Nov; 368(5):404-14. PubMed ID: 14557918
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide.
Paul AA; Witchel HJ; Hancox JC
Biochem Biophys Res Commun; 2001 Feb; 280(5):1243-50. PubMed ID: 11162661
[TBL] [Abstract][Full Text] [Related]
27. Prolongation of cardiac ventricular repolarization under paliperidone: how and how much?
Vigneault P; Kaddar N; Bourgault S; Caillier B; Pilote S; Patoine D; Simard C; Drolet B
J Cardiovasc Pharmacol; 2011 Jun; 57(6):690-5. PubMed ID: 21394035
[TBL] [Abstract][Full Text] [Related]
28. Block of HERG human K(+) channel and IKr of guinea pig cardiomyocytes by chlorpromazine.
Lee SY; Choi SY; Youm JB; Ho WK; Earm YE; Lee CO; Jo SH
J Cardiovasc Pharmacol; 2004 May; 43(5):706-14. PubMed ID: 15071359
[TBL] [Abstract][Full Text] [Related]
29. Pentamidine-induced long QT syndrome and block of hERG trafficking.
Kuryshev YA; Ficker E; Wang L; Hawryluk P; Dennis AT; Wible BA; Brown AM; Kang J; Chen XL; Sawamura K; Reynolds W; Rampe D
J Pharmacol Exp Ther; 2005 Jan; 312(1):316-23. PubMed ID: 15340016
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of gefitinib-induced QT prolongation.
Jie LJ; Li YD; Zhang HQ; Mao L; Xie HB; Zhou FG; Zhou TL; Xie D; Lin JL; Li GY; Cai BN; Zhang YH; Wang Y
Eur J Pharmacol; 2021 Nov; 910():174441. PubMed ID: 34474028
[TBL] [Abstract][Full Text] [Related]
31. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
Guo L; Guthrie H
J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
[TBL] [Abstract][Full Text] [Related]
32. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride.
Mohammad S; Zhou Z; Gong Q; January CT
Am J Physiol; 1997 Nov; 273(5):H2534-8. PubMed ID: 9374794
[TBL] [Abstract][Full Text] [Related]
33. A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the ion works HTTM system.
Guthrie H; Livingston FS; Gubler U; Garippa R
J Biomol Screen; 2005 Dec; 10(8):832-40. PubMed ID: 16234341
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of HERG potassium channels by the antimalarial agent halofantrine.
Tie H; Walker BD; Singleton CB; Valenzuela SM; Bursill JA; Wyse KR; Breit SN; Campbell TJ
Br J Pharmacol; 2000 Aug; 130(8):1967-75. PubMed ID: 10952689
[TBL] [Abstract][Full Text] [Related]
35. Electrophysiologic characterization of a novel hERG channel activator.
Su Z; Limberis J; Souers A; Kym P; Mikhail A; Houseman K; Diaz G; Liu X; Martin RL; Cox BF; Gintant GA
Biochem Pharmacol; 2009 Apr; 77(8):1383-90. PubMed ID: 19426677
[TBL] [Abstract][Full Text] [Related]
36. Targeted activation of human ether-à-go-go-related gene channels rescues electrical instability induced by the R56Q+/- long QT syndrome variant.
Venkateshappa R; Hunter DV; Muralidharan P; Nagalingam RS; Huen G; Faizi S; Luthra S; Lin E; Cheng YM; Hughes J; Khelifi R; Dhunna DP; Johal R; Sergeev V; Shafaattalab S; Julian LM; Poburko DT; Laksman Z; Tibbits GF; Claydon TW
Cardiovasc Res; 2023 Nov; 119(15):2522-2535. PubMed ID: 37739930
[TBL] [Abstract][Full Text] [Related]
37. The human ether-a-go-go-related gene (hERG) current inhibition selectively prolongs action potential of midmyocardial cells to augment transmural dispersion.
Yasuda C; Yasuda S; Yamashita H; Okada J; Hisada T; Sugiura S
J Physiol Pharmacol; 2015 Aug; 66(4):599-607. PubMed ID: 26348084
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of HERG K+ current and prolongation of the guinea-pig ventricular action potential by 4-aminopyridine.
Ridley JM; Milnes JT; Zhang YH; Witchel HJ; Hancox JC
J Physiol; 2003 Jun; 549(Pt 3):667-72. PubMed ID: 12740430
[TBL] [Abstract][Full Text] [Related]
39. Propranolol inhibits the human ether-a-go-go-related gene potassium channels.
Yao X; McIntyre MS; Lang DG; Song IH; Becherer JD; Hashim MA
Eur J Pharmacol; 2005 Sep; 519(3):208-11. PubMed ID: 16150441
[TBL] [Abstract][Full Text] [Related]
40. The Susceptibilities of Human Ether-à-Go-Go-Related Gene Channel with the G487R Mutation to Arrhythmogenic Factors.
Hisajima N; Hata Y; Kinoshita K; Fukushima T; Nishida N; Kano M; Tabata T
Biol Pharm Bull; 2015; 38(5):781-4. PubMed ID: 25947924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
